Moderna is trading 5.07% up at $237.77 on October 15, with no verified report tying the move to company-specific news and biotech strength offering a possible tailwind. - XBI is up 2.20% in the supplied market context. - Moderna reported starting a Phase 1 trial of its Bundibugyo Ebola vaccine, but coverage does not say it drove shares. - Broader market indicators are mixed, and available evidence points more toward sector sentiment.